Drug Profile
Latiglutenase - First Wave BioPharma
Alternative Names: ALV-003; IMGX 001; IMGX 002; IMGX-003; IMGX001 + IMGX002Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Stanford University
- Developer First Wave BioPharma
- Class Cysteine endopeptidases; Enzymes; Recombinant proteins
- Mechanism of Action Gluten modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease